Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Grifols, S.A. before investing.

In this article, we go over a few key elements for understanding Grifols, S.A.’s stock price such as:

• Grifols, S.A.’s current stock price and volume
• Why Grifols, S.A.’s stock price changed recently
• Upgrades and downgrades for GRFS from analysts
• GRFS’s stock price momentum as measured by its relative strength

About Grifols, S.A. (GRFS)

Before we jump into Grifols, S.A.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Want to learn more about Grifols, S.A.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Grifols, S.A..

What Caused Grifols, S.A. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 30, 2026, there was 1 analyst who downgraded Grifols, S.A.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Grifols, S.A.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Grifols, S.A.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Grifols, S.A.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Grifols, S.A. (GRFS) by visiting AAII Stock Evaluator.

Relative Price Strength of Grifols, S.A.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 30, 2026, Grifols, S.A. has a weighted four-quarter relative price strength of -2.93%, which translates to a Momentum Score of 46 and is considered to be Average.

Want to learn more about how Grifols, S.A. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Grifols, S.A. Stock Price: Bottom Line

As of May 1, 2026, Grifols, S.A.’s stock price is $8.190, which is down 0.61% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Grifols, S.A. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.